Viragen Reports Achievement of Key Avian Transgenics Milestone

Anti-Cancer Antibody Expressed In Chicken Eggs Promises to Revolutionize Drug Production

07-Jun-2005

Viragen, Inc., Roslin Institute (Scotland) and Oxford BioMedica PLC jointly announced a dramatic breakthrough in their pioneering project to develop Avian Transgenic Biomanufacturing with the report of a functional humanized antibody protein incorporated in the whites of eggs laid by a transgenic hen. This technology is expected to offer a lower-cost manufacturing alternative for the production of many protein drugs, with additional potential advantages in the quality of the products.

The therapeutic protein successfully expressed, using Oxford BioMedica's LentiVector® gene delivery system in this proprietary avian system, is a novel structure of an antibody in Viragen's product portfolio being designed to target malignant melanoma. Three other protein-drug candidates are included in ongoing avian expression studies to demonstrate the breadth of its capabilities, including two commercially marketed products, each of which realizes more than $2 billion in annual sales.

Viragen and Roslin confirmed qualitative and quantitative detection, and recovery of humanized antibody from the eggs. The analysis indicates that the expression levels measured are significantly higher than any previously published results for a therapeutic protein produced from an avian transgenic line.

The Project's scientific leader, Roslin Senior Scientist, Dr. Helen Sang, Ph.D., lauded the breakthrough, "We have long believed that this joint effort would develop an avian system capable of efficiently and economically producing human biopharmaceuticals, and with this major milestone achievement, I am even more convinced that we are developing an elite manufacturing platform that should emerge as a method of choice for many products."

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Ariadne Genomics and Jubilant Biosys Announce Strategic Alliance - Providing Curated Metabolic, Signaling, and Disease Pathway Databases as an Add-on to Pathway Analysis Software

Multiplicom receives €200,000 grant for novel non-invasive pre-natal test - IWT grant to support development of early aneuploidy detection during pregnancy

AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

Ori Biotech raises over $100 million in Series B funding - Innovative cell and gene therapy manufacturing platform

TranScrip Partners appoints David Oxlade as Chairman of the Board

Sequenom Announces Exclusive Licensing Agreement with Genomic Nanosystems for Digital PCR Technologies and Methods Patents

Intercell announces first data from its Phase I clinical trial with vaccine candidate to prevent Clostridium difficile infections - Second part of the study in the target population of elderly subjects will be initiated

Excellent early results in large OvPlex ovarian cancer biomarker study

Silence Therapeutics to receive $1.9m Milestone Payment as Pfizer and Quark commence Phase II Trial

Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board

Amorfix A(4) Assay Provides New Insights Into Alzheimer's Disease Pre-clinical Development Mouse Models - Amorfix Quantifies Rate of Accumulation of Amyloid in Seven Mouse Models of AD